Goldenwell Biotech, Inc.
GWLL
$0.77
-$0.13-14.44%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 100.00 | 100.00 | 62.30K | 37.30K | -100.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00 | 100.00 | 62.30K | 37.30K | -100.00 |
| Cost of Revenue | 174.80K | 174.80K | -100.00 | -100.00 | 0.00 |
| Gross Profit | -174.70K | -174.70K | 62.40K | 37.40K | 0.00 |
| SG&A Expenses | 112.40K | 117.50K | 131.20K | 121.30K | 128.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 287.10K | 292.20K | 131.10K | 121.20K | 128.60K |
| Operating Income | -287.10K | -292.20K | -68.70K | -83.80K | -128.50K |
| Income Before Tax | -279.70K | -300.60K | -79.20K | -94.30K | -139.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.28 | -0.30 | -0.08 | -0.09 | -0.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -279.70K | -300.60K | -79.20K | -94.30K | -139.00K |
| EBIT | -287.10K | -292.20K | -68.70K | -83.80K | -128.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 398.57M | 398.57M | 398.57M | 398.57M | 398.57M |
| Average Diluted Shares Outstanding | 398.57M | 398.57M | 398.57M | 398.57M | 398.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |